Drug-Induced Acute Renal Failure

Critical Care Nephrology, Second Edition

Volumn , Issue , 2008, Pages 317-324

  Burdmann, Emmanuel A ^a  

^a Sao Jose do Rio Preto Medical School   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80052053845     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-4252-5.50061-7     Document Type: Chapter

References (67)

1. JL Xue, F Daniels, RA Star, et al. (2006) Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. J Am Soc Nephrol 17 1135-1142.
2. RL Mehta, MT Pascual, S Soroko, et al., for the Program to Improve Care in Acute Renal Disease (2004) Spectrum of acute renal failure in the intensive care unit: The PICARD experience. Kidney Int 66 1613-1621.
3. WJ Santos, DM Zanetta, AC Pires, et al. (2006) Patients with ischaemic, mixed and nephrotoxic acute tubular necrosis in the intensive care unit—a homogeneous population? Crit Care 10 R68.
4. GM Chertow, E Burdick, M Honour, et al. (2005) Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 16 3365-3370.
5. F Pea, P Viale and M Furlanut (2005) Antimicrobial therapy in critically ill patients: A review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 44 1009-1034.
6. JFP Oliveira, JP Cipullo and EA Burdmann (2006) Aminoglycoside nephrotoxicity. Braz J Cardiovasc Surg 21 444-452.
7. MP Mingeot-Leclercq and PM Tulkens (1999) Aminoglycosides: Nephrotoxicity. Antimicrob Agents Chemother 43 1003-1012.
8. Martinez-Salgado C, Lopez-Hernandez FJ, Lopez-Novoa JM: Glomerular nephrotoxicity of aminoglycosides. Toxicol Appl Pharmacol. Epub ahead of print; doi:10.1016/j.taap.2007.05.004.
9. JFP Oliveira, CA Silva, CD Barbieri, et al. (2005) Risk factors for aminoglycoside (AG) nephrotoxicity (Nx) in the intensive care unit (ICU) [abstract]. J Am Soc Nephrol 16 539A.
10. MJ Izquierdo, C Gomez-Alamillo, F Ortiz, et al. (2006) Acute renal failure associated with use of inhaled tobramycin for treatment of chronic airway colonization with Pseudomonas aeruginosa. Clin Nephrol 66 464-467.
11. BN Patrick, MP Rivey and DR Allington (2006) Acute renal failure associated with vancomycin- and tobramycin-laden cement in total hip arthroplasty. Ann Pharmacother 40 2037-2042.
12. M Schetz, J Dasta, S Goldstein and T Golper (2005) Drug-induced acute kidney injury. Curr Opin Crit Care 11 555-565.
13. R Venkataraman and JA Kellum (2007) Prevention of acute renal failure. Chest 131 300-308.
14. AR Smyth and KH Tan (2006) Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev 3 CD002009
15. F Rougier, D Claude, M Maurin, et al. (2003) Aminoglycoside nephrotoxicity: Modeling, simulation, and control. Antimicrob Agents Chemother 47 1010-1016.
16. AW Chow and RM Azar (1994) Glycopeptides and nephrotoxicity. Intensive Care Med 20(Suppl 4), S23-S29.
17. LK Hidayat, DI Hsu, R Quist, et al. (2006) High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: Efficacy and toxicity. Arch Intern Med 166 2138-2144.
18. MJ Wood (2000) Comparative safety of teicoplanin and vancomycin. J Chemother 12(Suppl 5), 21-25.
19. BA Wicklow, MR Ogborn, IW Gibson and TD Blydt-Hansen (2006) Biopsy-proven acute tubular necrosis in a child attributed to vancomycin intoxication. Pediatr Nephrol 21 1194-1196.
20. VS Colares, RB Oliveira and RC Abdulkader (2006) Nephrotoxicity of vancomycin in patients with normal serum creatinine. Nephrol Dial Transplant 21 3608.
21. T Iwamoto, Y Kagawa and M Kojima (2003) Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol Pharm Bull 26 876-879.
22. ME Eichhorn, H Wolf, H Küchenhoff, et al. (2007) Secular trends in severe renal failure associated with the use of new antimicrobial agents in critically ill surgical patients. Eur J Clin Microbiol Infect Dis 26 395-402.
23. V Fanos and L Cataldi (2000) Amphotericin B–induced nephrotoxicity: A review. J Chemother 12 463-470.
24. G Deray (2002) Amphotericin B nephrotoxicity. J Antimicrob Chemother 49(Suppl 1), 37-41.
25. RD Goldman and G Koren (2004) Amphotericin B nephrotoxicity in children. J Pediatr Hematol Oncol 26 421-426.
26. S Harbarth, JP Burke, JF Lloyd, RS Evans, et al. (2002) Clinical and economic outcomes of conventional amphotericin B–associated nephrotoxicity. Clin Infect Dis 35 e120-e127.
27. AJ Ullmann, MA Sanz, A Tramarin, et al., for the Longitudinal Evaluation of Antifungal Drugs (LEAD I) Investigators (2006) Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 43 e29-e38.
28. CY Chen, RN Kumar, YH Feng, et al. (2006) Treatment outcomes in patients receiving conventional amphotericin B therapy: A prospective multicentre study in Taiwan. J Antimicrob Chemother 57 1181-1188.
29. RH Berdichevski, LB Luis, L Crestana and RC Manfro (2006) Amphotericin B–related nephrotoxicity in low-risk patients. Braz J Infect Dis 10 94-99.
30. J Echevarria, C Seas, M Cruz, et al. (2006) Oral rehydration solution to prevent nephrotoxicity of amphotericin B. Am J Trop Med Hyg 75 1108-1112.
31. F Saliba (2006) Antifungals and renal safety—getting the balance right. Int J Antimicrob Agents 27(Suppl 1), 21-24.
32. JM Aguado, C Lumbreras, D Gonzalez-Vidal and for the Grupo de Farmacovigilancia de Abelcet (2004) Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: A pharmacosurveillance study in Spain. Clin Microbiol Infect 10 785-790.
33. ME Eichhorn, H Wolf, H Kuchenhoff, et al. (2007) Secular trends in severe renal failure associated with the use of new antimicrobial agents in critically ill surgical patients. Eur J Clin Microbiol Infect Dis 26 395-402.
34. ME Falagas and SK Kasiakou (2006) Toxicity of polymyxins: A systematic review of the evidence from old and recent studies. Crit Care 10 R27.
35. TM Arnold, GN Forrest and KJ Messmer (2007) Polymyxin antibiotics for gram-negative infections. Am J Health Syst Pharm 64 819-826.
36. ME Falagas, SK Kasiakou, DP Kofteridis, et al. (2006) Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. Eur J Clin Microbiol Infect Dis 25 596-599.
37. CAC Mendes, J Cordeiro and EA Burdmann (2006) Prevalence and risk factors for polymyxin B (Poly B) nephrotoxicity [abstract]. J Am Soc Nephrol 17 164A.
38. CM Wyatt and PE Klotman (2006) Antiretroviral therapy and the kidney: Balancing benefit and risk in patients with HIV infection. Expert Opin Drug Saf 5 275-287.
39. R Valle and L Haragsim (2006) Nephrotoxicity as a complication of antiretroviral therapy. Adv Chronic Kidney Dis 13 314-319.
40. SM Said, SH Nasr, R Samsa, et al. (2007) Nephrotoxicity of antiretroviral therapy in an HIV-infected patient. Kidney Int 71 1071-1075.
41. A Barrios, T García-Benayas, J González-Lahoz and V Soriano (2004) Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS 18 960-963.
42. HC Côté, AB Magil, M Harris, et al. (2006) Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy. Antivir Ther 11 79-86.
43. QA Rao and JH Newhouse (2006) Risk of nephropathy after intravenous administration of contrast material: A critical literature analysis. Radiology 239 392-397.
44. EM Levy, CM Viscoli and RI Horwitz (1996) The effect of acute renal failure on mortality. A cohort analysis. JAMA 275 1489-1494.
45. PA McCullough, R Wolyn, LL Rocher, et al. (1997) Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med 103 368-375.
46. RW Katzberg (2005) Contrast medium–induced nephrotoxicity: Which pathway? Radiology 235 752-755.
47. R Schräder (2005) Contrast material–induced renal failure: An overview. J Interv Cardiol 18 417-423.
48. R Mehran and E Nikolsky (2006) Contrast-induced nephropathy: Definition, epidemiology, and patients at risk. Kidney Int Suppl (100), S11-S15.
49. C Davidson, F Stacul, PA McCullough, et al., for the CIN Consensus Working Panel (2006) Contrast medium use. Am J Cardiol 98 42K-58K.
50. N Pannu, N Wiebe, M Tonelli and for the Alberta Kidney Disease Network (2006) Prophylaxis strategies for contrast-induced nephropathy. JAMA 295 2765-2779.
51. C Mueller (2006) Prevention of contrast-induced nephropathy with volume supplementation. Kidney Int Suppl (100), S16-S19.
52. GJ Merten, WP Burgess, LV Gray, et al. (2004) Prevention of contrast-induced nephropathy with sodium bicarbonate: A randomized controlled trial. JAMA 291 2328-2334.
53. J Lin and JV Bonventre (2005) Prevention of radiocontrast nephropathy. Curr Opin Nephrol Hypertens 14 105-110.
54. R Solomon and W Dumouchel (2006) Contrast media and nephropathy: Findings from systematic analysis and Food and Drug Administration reports of adverse effects. Invest Radiol 41 651-660.
55. JT Van Praet and AS De Vriese (2007) Prevention of contrast-induced nephropathy: A critical review. Curr Opin Nephrol Hypertens 16 336-347.
56. PT Vaitkus and C Brar (2007) N-acetylcysteine in the prevention of contrast-induced nephropathy: Publication bias perpetuated by meta-analyses. Am Heart J 153 275-280.
57. A Benko, M Fraser-Hill, P Magner, et al. (2007) Canadian Association of Radiologists: Consensus guidelines for the prevention of contrast-induced nephropathy. Can Assoc Radiol J 58 79-87.
58. G Marenzi, I Marana, G Lauri, et al. (2003) The prevention of radiocontrast-agent–induced nephropathy by hemofiltration. N Engl J Med 349 1333-1340.
59. G Marenzi, G Lauri, J Campodonico, et al. (2006) Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med 119 155-162.
60. DC Brater (2002) Anti-inflammatory agents and renal function. Semin Arthritis Rheum 32(3 Suppl 1), 33-42.
61. A Whelton (1999) Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications. Am J Med 106 13S-24S.
62. GK Sandhu and CA Heyneman (2004) Nephrotoxic potential of selective cyclooxygenase-2 inhibitors. Ann Pharmacother 38 700-704.
63. RD Toto (1994) Renal insufficiency due to angiotensin-converting enzyme inhibitors. Miner Electrolyte Metab 20 193-200.
64. CD Hanevold (2006) Acute renal failure during lisinopril and losartan therapy for proteinuria. Pharmacotherapy 26 1348-1351.
65. C Stirling, J Houston, S Robertson, et al. (2003) Diarrhoea, vomiting and ACE inhibitors: An important cause of acute renal failure. J Hum Hypertens 17 419-423.
66. CS Cruz, LS Cruz, GR Silva and CA Marcilio de Souza (2007) Incidence and predictors of development of acute renal failure related to treatment of congestive heart failure with ACE inhibitors. Nephron Clin Pract 105 c77-c83.
67. V Adhiyaman, M Asghar, A Oke, et al. (2001) Nephrotoxicity in the elderly due to co-prescription of angiotensin converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs. J R Soc Med 94 512-514.